| Compound Information | SONAR Target prediction |
| Name: | Quinacrine dihydrochloride |
| Unique Identifier: | LOPAC 00629 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | C23Cl3H32N3O |
| Molecular Weight: | 440.624 g/mol |
| X log p: | 13.398 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 24.83 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 4 |
| Rotatable Bond Count: | 9 |
| Canonical Smiles: | Cl.Cl.CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc21 |
| Class: | Neurotransmission |
| Action: | Inhibitor |
| Selectivity: | MAO |
| Generic_name: | Quinacrine |
| Chemical_iupac_name: | N--(6-chloro-2-methoxy-acridin-9-yl)-N,N-diethyl-pentane-1,4-diamine |
| Drug_type: | Approved Drug |
| Kegg_compound_id: | C07339 |
| Drugbank_id: | APRD00317 |
| Melting_point: | 248-250 oC |
| H2o_solubility: | Slight |
| Logp: | 5.388 |
| Isoelectric_point: | 10.3 |
| Cas_registry_number: | 83-89-6 |
| Drug_category: | Antihelmintics; Antiprotozoals; Antineoplastic Agents; Antinematodal Agents; Antimalarials; Anticestodal Agents; Enzyme Inhibitors |
| Indication: | For the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions. |
| Pharmacology: | Quinacrine has been used as an antimalarial drug and as an antibiotic. It is used to treat giardiasis, a protozoal infection of the intestinal tract, and certain types of lupus erythematosus, an inflammatory disease that affects the joints, tendons, and other connective tissues and organs. Quinacrine may be injected into the space surrounding the lungs to prevent reoccurrence of pneumothorax. The exact way in which quinacrine works is unknown. It appears to interfere with the parasite-s metabolism. |
| Mechanism_of_action: | The exact mechanism of antiparasitic action is unknown; however, quinacrine binds to deoxyribonucleic acid (DNA) in vitro by intercalation between adjacent base pairs, inhibiting transcription and translation to ribonucleic acid (RNA). Quinacrine does not appear to localize to the nucleus of Giaridia trophozoites, suggesting that DNA binding may not be the primary mechanism of its antimicrobial action. Fluorescence studies using Giardia suggest that the outer membranes may be involved. Quinacrine inhibits succinate oxidation and interferes with electron transport. In addition, by binding to nucleoproteins, quinacrine suppress the lupus erythematous cell factor and acts as a strong inhibitor of cholinesterase. |
| Organisms_affected: | Parasitic protozoa and helminths |
| Found: 8 active | as graph: single | with analogs | 1 2 3 4 5 6 7 8 Next >> |
| Species: | 4932 |
| Condition: | BY4743 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.5144±0.22288 |
| Normalized OD Score: sc h | 0.6410±0.297543 |
| Z-Score: | -10.0279±8.60495 |
| p-Value: | 0.0000401922 |
| Z-Factor: | -2.04176 |
| Fitness Defect: | 10.1218 |
| Bioactivity Statement: | Outlier |
| ps |
| DBLink | Rows returned: 8 | 1 2 Next >> |
| 237 | N--(6-chloro-2-methoxy-acridin-9-yl)-N,N-diethyl-pentane-1,4-diamine |
| 6239 | N--(6-chloro-2-methoxy-acridin-9-yl)-N,N-diethyl-pentane-1,4-diamine dihydrochloride |
| 22527 | 4-(6-chloro-2-methoxy-acridin-9-yl)ammoniopentyl-diethyl-azanium dichloride |
| 446536 | (4R)-N--(6-chloro-2-methoxy-acridin-9-yl)-N,N-diethyl-pentane-1,4-diamine |
| 2725002 | N--(6-chloro-2-methoxy-acridin-9-yl)-N,N-diethyl-pentane-1,4-diamine dihydrate dihydrochloride |
| 5351141 | N--(6-chloro-2-methoxy-acridin-9-yl)-N,N-diethyl-pentane-1,4-diamine hydrochloride |
| internal high similarity DBLink | Rows returned: 1 |
| SPE01500522 | 1.0000 |
| active | Cluster 1527 | Additional Members: 5 | Rows returned: 2 |
| SPE01500522 | 0 |
| Prest650 | 0 |
Service provided by the
Mike Tyers Laboratory